Ikena Oncology, Inc.

NASDAQ
IKNA
paper.types.company
Rentabilité sur six mois: -31.36%
Rendement en dividendes: 0%
Secteur: Healthcare

1.16 $

-0.015 $ -1.28%
1.03 $
1.85 $

paper.min_max_per_year

Calendrier des promotions Ikena Oncology, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Ikena Oncology, Inc.

Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas.

plus de détails
Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2021-03-26
ISIN
US45175G1085
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 9.52 1
P/BV 0.6285 10
P/E 0 0
Efficacité
Nom Signification Grade
ROA -29.52 0
ROE -33.3 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.1275 10
Debt/Ratio 0.0531 10
Debt/Equity 0.1237 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % -33.62 0
Rentabilité Ebitda, % 33.42 5
Rentabilité EPS, % -20.3 0
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 1.18 $ 0 $ 0 $ -1.28 % 0 % 0 %
common.calendar.number_days.7d 1.15 $ 0 $ 0 $ 0.87 % 0 % 0 %
common.calendar.number_days.30d 1.27 $ 1.08 $ 1.17 $ -8.66 % 0 % 0 %
common.calendar.number_days.90d 1.37 $ 1.03 $ 1.39 $ -15.33 % 0 % 0 %
common.calendar.number_days.180d 1.69 $ 1.03 $ 1.7 $ -31.36 % 0 % 0 %
common.calendar.number_days.1y 1.67 $ 1.03 $ 1.85 $ -30.54 % 0 % 0 %
common.calendar.number_days.3y 3.29 $ 1.03 $ 7.31 $ -64.74 % 0 % 0 %
common.calendar.number_days.5y 0 $ 1.03 $ 32 $ 0 % 0 % 0 %
common.calendar.number_days.10y 0 $ 1.03 $ 32 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 1.55 $ 1.03 $ 1.69 $ -25.16 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Mark Manfredi Ph.D. President, CEO & Director 810.69k 1971 (54 année)
Dr. Jotin Marango M.D., Ph.D. CFO & Head of Corporate Development 577.12k 1979 (46 années)
Mr. Bob Lally Senior Vice President of Finance & Operations N/A
Mr. Jeffrey Ecsedy Ph.D. Chief Development Officer N/A 1970 (55 années)
Mr. David Damphousse M.S. Senior Vice President of Clinical Development Operations N/A
Mr. Valdas Jurkauskas Ph.D. Senior Vice President of Technical Operations N/A
Dr. Caroline Germa M.D., Ph.D. Chief Medical Officer N/A 1972 (53 année)
Ms. Rebecca Cohen Vice President of Investor Relations, Corporate Strategy & Communication

Informations sur l'entreprise

Adresse: United States, Boston. MA, 645 Summer Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://ikenaoncology.com